BD Diagnostics Acquires Kiestra and Expands Microbiology Portfolio

BD Diagnostics (Franklin Lakes, NJ, USA) has acquired Kiestra (Drachtan, the Netherlands), expanding the company microbiology portfolio to include new automated instrumentation technologies, which will enable it to offer total lab automation solutions to hospitals and laboratories worldwide.

Kiestra Lab Automation BV, which designs, develops, manufactures, markets, and sells lab automation solutions for the microbiology lab, complements BD’s microbiology portfolio of instruments, reagents, and supplies. Kiestra offers two lines of automated solutions: Total Lab Automation (TLA) and Work Cell Automation (WCA). Total Lab Automation is designed to significantly increase overall microbiology lab productivity, streamline workflow, and shorten the time to results. Kiestra’s Work Cell solutions will offer customers a modular and scalable approach to automate their lab within current space and budget constraints.

“We look forward to joining the BD team to expand automation across the entire microbiology and infectious disease testing process,” said Jetze Botma, vice president, microbiology laboratory automation, who served until the acquisition as CEO, KIESTRA Lab Automation. “Together with BD, we now have the opportunity to integrate automation across microbiology informatics, instruments, and consumables for maximum workflow efficiency, and have access to the global arena.”

Kiestra Lab Automation BV, which designs, develops, manufactures, markets, and sells lab automation solutions for the microbiology lab, complements BD’s microbiology portfolio of instruments, reagents, and supplies. Kiestra offers two lines of automated solutions: Total Lab Automation (TLA) and Work Cell Automation (WCA). Total Lab Automation is designed to significantly increase overall microbiology lab productivity, streamline workflow, and shorten the time to results. Kiestra’s Work Cell solutions will offer customers a modular and scalable approach to automate their lab within current space and budget constraints.

“We look forward to joining the BD team to expand automation across the entire microbiology and infectious disease testing process,” said Jetze Botma, vice president, microbiology laboratory automation, who served until the acquisition as CEO, KIESTRA Lab Automation. “Together with BD, we now have the opportunity to integrate automation across microbiology informatics, instruments, and consumables for maximum workflow efficiency, and have access to the global arena.”

BD is a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery, and production of new drugs and vaccines.

Related Links:
BD Diagnostics
Kiestra